Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 99.60M | 83.57M | 72.05M | 67.45M | 59.26M |
Gross Profit | 61.59M | 50.78M | 42.80M | 41.49M | 35.27M |
EBITDA | 9.21M | -3.89M | -16.74M | -25.45M | -18.34M |
Net Income | 8.55M | -4.94M | -16.54M | -27.13M | -19.93M |
Balance Sheet | |||||
Total Assets | 68.28M | 54.96M | 54.06M | 57.84M | 38.36M |
Cash, Cash Equivalents and Short-Term Investments | 44.51M | 27.17M | 20.29M | 28.02M | 16.50M |
Total Debt | 2.65M | 3.28M | 4.26M | 4.70M | 1.64M |
Total Liabilities | 22.18M | 26.51M | 25.39M | 26.11M | 21.93M |
Stockholders Equity | 46.09M | 28.46M | 28.67M | 31.73M | 16.42M |
Cash Flow | |||||
Free Cash Flow | 11.95M | 6.97M | -15.43M | -24.57M | -10.74M |
Operating Cash Flow | 12.11M | 7.12M | -15.10M | -24.16M | -10.60M |
Investing Cash Flow | -143.00K | -143.00K | -334.00K | -409.00K | -165.00K |
Financing Cash Flow | 5.37M | -90.00K | 7.65M | 36.09M | 8.65M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $1.06B | 80.02 | 33.47% | ― | 29.77% | ― | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 5.48% | 11.72% | -20.69% | |
50 Neutral | $460.27M | ― | -1.44% | 850.08% | 1.98% | 63.69% | |
49 Neutral | $629.01M | ― | -45.75% | ― | -11.76% | -15.82% | |
48 Neutral | $491.34M | ― | -37.13% | ― | -38.14% | 29.69% | |
39 Underperform | $482.57M | ― | ― | -25.10% | -7.06% | ||
33 Underperform | $654.11M | ― | -71.44% | ― | ― | 19.94% |
At the Annual Meeting of Stockholders on June 24, 2025, Niagen Bioscience‘s shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the available shares by 4.75 million. Additionally, the Employee Stock Purchase Plan was approved, allowing employees to purchase shares at a discounted rate. These decisions are expected to enhance employee engagement and align stakeholder interests with the company’s growth objectives.
The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
On May 7, 2025, Niagen Bioscience, Inc. reported its financial results for the first quarter of 2025, revealing a significant year-over-year increase in net sales by 38% to $30.5 million, driven by strong demand for its Tru Niagen® and Niagen® ingredient products. The company achieved a gross margin of 63.4% and net income of $5.1 million, marking a substantial improvement from the previous year. Additionally, Niagen Bioscience announced an increased full-year outlook for 2025, expecting net sales growth between 20% and 25%, and highlighted its strategic rebranding and expansion of its NAD+ precursor patent portfolio, reinforcing its leadership in the healthy aging sector.